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Abstract
Background: Recent developments in genomic sequencing have advanced our understanding of the mutations
underlying human malignancy. Melanoma is a prototype of an aggressive, genetically heterogeneous cancer
notorious for its biologic plasticity and predilection towards developing resistance to targeted therapies. Evidence is
rapidly accumulating that dysregulated epigenetic mechanisms (DNA methylation/demethylation, histone modification,
non-coding RNAs) may play a central role in the pathogenesis of melanoma. Therefore, we sought to characterize the
frequency and nature of mutations in epigenetic regulators in clinical, treatment-naïve, patient melanoma specimens
obtained from one academic institution.
Results: Targeted next-generation sequencing for 275 known and investigative cancer genes (of which 41 genes, or
14.9 %, encoded an epigenetic regulator) of 38 treatment-naïve patient melanoma samples revealed that
22.3 % (165 of 740) of all non-silent mutations affected an epigenetic regulator. The most frequently mutated
genes were BRAF, MECOM, NRAS, TP53, MLL2, and CDKN2A. Of the 40 most commonly mutated genes, 12 (30.0 %)
encoded epigenetic regulators, including genes encoding enzymes involved in histone modification (MECOM, MLL2,
SETD2), chromatin remodeling (ARID1B, ARID2), and DNA methylation and demethylation (TET2, IDH1). Among the 38
patient melanoma samples, 35 (92.1 %) harbored at least one mutation in an epigenetic regulator. The genes with
the highest number of total UVB-signature mutations encoded epigenetic regulators, including MLL2 (100 %, 16 of 16)
and MECOM (82.6 %, 19 of 23). Moreover, on average, epigenetic genes harbored a significantly greater number of
UVB-signature mutations per gene than non-epigenetic genes (3.7 versus 2.4, respectively; p = 0.01). Bioinformatics
analysis of The Cancer Genome Atlas (TCGA) melanoma mutation dataset also revealed a frequency of mutations in
the 41 epigenetic genes comparable to that found within our cohort of patient melanoma samples.
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Conclusions: Our study identified a high prevalence of somatic mutations in genes encoding epigenetic
regulators, including those involved in DNA demethylation, histone modification, chromatin remodeling,
and microRNA processing. Moreover, UVB-signature mutations were found more commonly among epigenetic
genes than in non-epigenetic genes. Taken together, these findings further implicate epigenetic mechanisms,
particularly those involving the chromatin-remodeling enzyme MECOM/EVI1 and histone-modifying enzyme
MLL2, in the pathobiology of melanoma.
Keywords: Melanoma, Next-generation sequencing (NGS), Epigenetics, MECOM (MDS1 and EV1 complex
locus), MLL2, Ten-eleven translocation (TET), Isocitrate dehydrogenase 2 (IDH2), 5-hydroxymethylcytosine, DNA
demethylation
Background
Despite advancements in our understanding of the molecu-
lar mechanisms underlying melanogenesis, disease progres-
sion, and therapeutic response, melanoma remains one of
the deadliest forms of human malignancy [1]. Identification
of frequent mutations in the gene encoding the serine/
threonine-protein kinase B-Raf (BRAF) in melanoma [2]
led to the development of targeted inhibitors with improved
survival demonstrated in phase III clinical trials demon-
strating improved overall survival [3]. However, soon after
the discovery of frequent BRAF V600E mutations in melan-
oma, the same mutation was found at higher frequencies in
benign and dysplastic melanocytic nevi [4]. Since then,
BRAF mutations, alone, have become understood to be “in-
sufficient” to induce tumor progression beyond the benign
melanocytic nevus stage [5].
Despite initial clinical response after targeted, single
agent therapy, the subsequent development of resistance
in patients being treated for metastatic melanoma is, essen-
tially, universal [6]. This is largely attributed to the develop-
ment and progression of chemoresistant subpopulations,
enabled, in part, by unique biological characteristics inher-
ent to malignant melanoma [7]. Complicating matters is
that approximately one in every five patients harboring
BRAF V600 mutant melanoma will have disease that is in-
trinsically resistant to BRAF inhibition and will be found to
have progressed on therapy at first follow-up assessment
[6]. While the combined use of targeted therapies (BRAF
and/or MEK inhibition) [7–9] as well as immunotherapies
(monoclonal antibodies directed at CTLA-4 and PD-1/PD-
L1) have shown significantly improved outcomes for mel-
anoma patients with advanced disease [10, 11], evidence
implicating dysregulated epigenetic mechanisms in the
pathogenesis of melanoma and other malignancies is also
accumulating at a rapid pace [12, 13]. This growing body of
literature has significant translational potential to elucidate
novel pathogenic mechanisms in melanoma and deserves
thorough investigation, as therapeutically targeting epi-
genetic mechanisms [14, 15] in combination with other
targeted or immunotherapeutic modalities may be neces-
sary to achieve sustainable clinical remission [16–18].
Recent advancements in next-generation sequencing
(NGS) technologies have facilitated whole-genome, whole-
exome, and whole-transcriptome analyses that could enable
personalized diagnostic and therapeutic strategies. These
technologies have demonstrated substantial power and
sensitivity in identifying novel mutated genes in melanoma
and have even been used to gain insight into mechanisms
of primary (intrinsic) [17] and secondary (acquired) che-
moresistance in select melanoma patients [7, 19]. Moreover,
developments in computational processing and statistical
analytics have also enabled the dissection of “driver” muta-
tions (those that confer a fitness advantage to a particular
tumor cell) from “passenger” mutations (those that do not)
[20]. Indeed, such efforts to enhance molecular precision
while characterizing the genetic and epigenetic landscape
within an individual patient’s melanoma may be necessary
to help guide combinatorial therapies [21].
Herein, we describe the targeted NGS platform devised
at our institution to sequence 275 known and investigative
cancer genes (“Oncopanel”, Brigham and Women’s Hos-
pital and Dana–Farber Cancer Institute) in patients being
evaluated for the management of melanoma and report the
frequency and nature of gene mutations identified. A list of
the genes tested for by the Oncopanel platform is provided
in Additional file 1. A substantial fraction (14.9 %, 41
of 275) of these genes encode either well-established or
recently-described epigenetic regulators, including those
involved in DNA methylation and demethylation, histone
modification, chromatin remodeling, and non-coding
RNAs. In light of rapidly accumulating evidence for the in-
volvement of dysregulated epigenetic mechanisms in mel-
anoma pathogenesis [12, 13], we sought, specifically, to
characterize the prevalence and nature of mutations in
this select panel of epigenetic regulators within our cohort
of patient melanoma samples.
Results
Patient demographic, clinical, and histopathologic
information
A total of 38 patient melanoma samples (n = 38), each ob-
tained from 38 unique patients, were available for analysis.
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Of these, 13 were primary cutaneous melanomas (nP = 13)
and the remaining 25 were obtained from metastatic sites
(nM= 25). Patients ranged in age from 21 to 83 years
(mean, 60.9; median, 62; SD, 13.06). Primary cutaneous
melanoma samples ranged in Breslow depth and mitotic
rate from 0.67 to 7.50 mm (mean, 3.66 mm; median, 3.1;
SD, 1.94) and from 1 to 17 mitoses/mm2 (mean, 5.3; me-
dian, 4; SD, 4.5). Six of the primary melanomas (46.2 %, 6
of 13) had histologic evidence of ulceration. Of the pa-
tients whose primary melanomas had been sequenced, five
(38.5 %) had also gone on to develop metastatic disease.
The vast majority of metastatic melanoma tissues samples
were obtained from lymph nodes (44 %, 11 of 25), while
the remaining metastases were obtained from the thorax
(i.e., lung, chest wall, 16 %, 4 of 25), abdomen (i.e., mesen-
tery, adrenal gland, 4 of 25, 16 %), central nervous system
(i.e., brain, brainstem, 12 %, 3 of 25), or subcutaneous
tissue (i.e., in transit metastasis) (12 %, 3 of 25).
General mutation distribution and characteristics
Collectively across all 38 patient samples, a total of 740
non-silent mutations were identified in 204 of the 275
(74.2 %) genes originally tested for. An average of approxi-
mately 20 mutations (median, 15.5; range, 3 to 132; stand-
ard deviation, 21.5) was identified per patient melanoma
sample. A graph summarizing the distribution of mutation
types is shown in Fig. 1. The vast majority of mutations
were missense mutations (84.7 %, 627 of 740), followed
by nonsense mutations (8.9 %, 66 of 740), insertions or
deletions resulting in frameshift (2.0 %, 14 of 740), and
splice site mutations (2.0 %, 15 of 740). The largest per-
centage of nonsense mutations occurred in well-known
tumor suppressor genes NF1 (12.1 %, 8 of 66), CDKN2A
(10.6 %, 7 of 66), and TP53 (9.1 %, 6 of 66).
The top 40 most frequently mutated genes, as deter-
mined by the number and frequency of total mutations,
are graphically represented in Fig. 2. BRAF (42.1 % of
patient samples, 16 of 38), MECOM (36.8 %, 14 of 38),
NRAS (36.8 %, 14 of 38), TP53 (31.6 %, 12 of 38), MLL2
(29.0 %, 11 of 38), as well as CDKN2A (29.0 %, 11 of 38)
were among the most commonly mutated genes among
the patient melanoma samples. Of these genes, MECOM,
BRAF, and MLL2 harbored the greatest number of total
mutations (23, 19, 16, respectively).
High frequency of mutations identified in key epigenetic
regulators
Of interest, 22.3 % (165 of 740) of all mutations occurred
in genes encoding epigenetic regulators. Mutations in
genes encoding histone-modifying proteins were the most
common (64.2 %, or 106 of 165 epigenetic gene mutations,
which accounted for 14.3 %, or 106 of all 740 identified
mutations), including MECOM and MLL2 listed above,
followed by chromatin remodeling proteins (24.2 %, 40 of
165), DNA methylation/demethylation enzymes (9.1 %, 15
of 165), and enzymes involved in miRNA processing
(2.4 %, 4 of 165). A summary of the frequency of mutated
epigenetic genes categorized by their functional epigenetic
Fig. 1 Bar graph summarizing distribution of mutation types in our 38 patient melanoma samples
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classification is illustrated in Fig. 3. At least one mutation
in an epigenetic gene was found in 92.1 % (35 of 38) of pa-
tients, and 25 of these patients (65.7 % of all samples) had
more than one epigenetic regulatory gene mutated.
Of all the mutated genes identified, 17.2 % (35 of 204)
encoded epigenetic regulators, whereas 14.9 % (41 of 275)
of the genes tested by our Oncopanel were epigenetic in
nature. Moreover, within the top 40 most frequently mu-
tated genes, 30.0 % (12 of 40) of the genes encoded epi-
genetic regulators (Fig. 2). A two-sample z test comparing
the proportion of epigenetic regulators within the top 40
(30 %, 12 of 40) compared to that within the original panel
of tested genes (14.9 %, 41 of 275) revealed a statistically
significant difference (p = 0.017, z score = 2.4) between
these two groups. Ten of 12 (81.2 %) of the epigenetic
genes within the top 40 were found to encode either
histone-modifying proteins (e.g., MECOM, MLL2, SETD2)
or subunits of chromatin-remodeling complexes (e.g.,
ARID1B, ARID2). Two of 12 (16.7 %) of these epigenetic
genes within the top 40 encode enzymes involved in active
DNA demethylation (TET2, IDH1). Furthermore, 30.8 %
(4 of 13) of all genes containing an insertion or deletion
resulting in frameshift encoded epigenetic regulators,
including histone-modifying enzymes (SETD2, CREBBP,
MLL) and DNA methyltransferase 3A DNMT3A.
Analysis of epigenetic mutations and key
clinicopathologic parameters
A summary graphic illustrating the spectrum of epigenetic
genes mutated within each patient melanoma sample as
well as the clinical and histopathologic data corresponding
to each patient’s case is presented in Fig. 4. Our analysis
did not identify statistically significant relationships be-
tween mutations in specific epigenetic genes and key
histologic parameters of primary cutaneous melanoma,
such as the Breslow depth, mitotic rate, or the presence/
absence of ulceration; nor did it reveal any specific epigen-
etic mutational signature of either primary or metastatic
melanomas within the limited number of samples in our
study. Nonetheless, ingenuity pathway analysis revealed a
complex mechanistic interplay between several of our
most frequently mutated epigenetic regulators and the
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prevalence of mutations in each epigenetic regulator is
also graphically represented (Fig. 5).
High frequency of UVB-pattern mutations particularly
found among key epigenetic regulators
Of all the mutations identified, 73.1 % (541 of 740) bore
the signature of UVB damage. A single C > T nucleotide
substitution was the most common (70.3 %, 520 of 740),
followed by CC > TT tandem dinucleotide mutation
(2.2 %, 12 of 541), and C > T missense mutations within
a dinucleotide substitution (1.7 %, 9 of 541). In contrast,
only 4.9 % (36 of 740) of all mutations were G > T single
nucleotide variant transitions, the signature of UVA-
induced DNA damage. The genes with the greatest
number of total UVB-signature mutations encoded epi-
genetic regulators, including MLL2 (100 %, 16 of 16)
and MECOM (82.6 %, 19 of 23). The spectrum of UV-
signature mutations in non-epigenetic and epigenetic
genes is provided in Figs. 6 and 7, respectively.
Collectively, non-epigenetic genes harbored a mean of
2.4 UVB-signature mutations per gene (median, 2; mode,
1; standard deviation, 2.5) whereas epigenetic genes har-
bored an average of 3.7 (median, 3; mode, 3; standard
deviation, 3.9) (Fig. 8). An unpaired, two-sample t test
comparing the average number of UVB-signature muta-
tions per gene in non-epigenetic versus epigenetic genes
revealed a statistically significant difference (p = 0.014)
between the two groups. Of note, 81.8 % (9 of 11) of
CDKN2A mutations and 84.6 % (11 of 13) of TP53
mutations bore the UVB-signature. Interestingly, none
of the NRAS mutations (0 of 14) and only 47.4 % (9 of
19) of BRAF mutations resembled the UVB-signature
mutation.
Bioinformatics analysis of existing melanoma mutation
datasets
Targeted analysis of melanoma mutation data, publicly
available online through The Cancer Genome Atlas
database (TCGA, http://www.cbioportal.org) was also
performed on 278 melanoma samples provided by the
TCGA (nT = 278) and 121 samples made available
through the Broad Institute (Cambridge, MA) (nB = 121)
[22, 23]. We found that the frequency of mutations in
genes among our top 40 most frequently mutated was,
overall, comparable to that found in 97.1 % (270 of 278)
of TCGA melanoma samples (Fig. 9) and 95 % (115 of
121) of samples provided by the Broad Institute (Fig. 10),
although eight of our top 40 (20 %) genes were not avail-
able through this database. Notably, however, the preva-
lence of BRAF mutations was higher in the TCGA and
Broad Institute cohorts (51 and 63 %, respectively) than
in our dataset (42 %). In addition, MECOM mutations
were found less frequently in the TCGA and Broad Insti-
tute cohorts (20 and 16 %, respectively).
Furthermore, a focused analysis of mutations in the 41
epigenetic genes tested by our Oncopanel in the TCGA
Fig. 3 Frequency of mutated epigenetic genes organized by functional epigenetic category
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and Broad cohorts revealed a comparable frequency of
mutations (Figs. 11 and 12). In keeping with our data,
MECOM, MLL2 (KMT2D), MLL (KMT2A), ARID2, and
CUX1 were among the most frequently mutated epigen-
etic genes in the TCGA and Broad Institute melanoma
cohorts. In addition, the vast majority of samples in both
the TCGA (83.1 %, 231 of 278) and Broad Institute
(69.4 %, 84 of 121) cohorts harbored at least one muta-
tion in one of the tested epigenetic genes.
Discussion
The incidence of melanoma, unlike many other poten-
tially preventable cancers, is steadily increasing world-
wide, with an estimated 76,100 new cases diagnosed in
the USA in 2014 alone [1]. While accounting for less
than 2 % of all skin cancers, melanoma accounts for the
vast majority of skin cancer deaths [1]. Major risk factors
for melanoma include those that are genetic and envir-
onmental in nature, such as having a personal or family
history of melanoma, five or more “atypical” nevi, having
numerous (>50) melanocytic nevi, fair-colored skin, as
well as either a history of blistering sun burns during
childhood/adolescence and/or a history of indoor tan-
ning bed use [24]. Epidemiological evidence increasingly
implicates UV radiation in melanoma pathogenesis, as
was recently detailed in a meta-analysis that demonstrated
an increased risk of melanoma in airline pilots and cabin
crew (thought to be related to elevated levels of cosmic
and UV radiation exposure) [25]. Approximately 10 % of
melanomas occur in a familial setting, and germline muta-
tions to a number of genes, including CDKN2A (9p21),
CDK4 (12q14), BAP1 (3p21), TERT promoter (5p15) [26],
and most recently POT1 (7q31) [27], have been demon-
strated to predispose individuals to developing cutaneous
melanoma in addition to other melanoma subtypes (e.g.,
BAP1 and metastatic uveal melanoma) as well as numer-
ous atypical melanocytic nevi (CDKN2A, CDK4) [28].
Collectively, these observations reinforce that the patho-
genesis of melanoma is complex, involving both genetic
and non-heritable (e.g., environmental) factors.
The most frequently mutated genes within our cohort re-
semble those reported in previous studies [20, 29] as well
as through data available through the Sanger Institute
Catalogue Of Somatic Mutations in Cancer (COSMIC)
database (http://www.sanger.ac.uk/) and the NIH/NCI
TCGA melanoma mutation database (http://www.cbio
portal.org) [22, 23, 30]. The well-known oncogenes NRAS
and BRAF as well as the tumor suppressor genes CDKN2A
Fig. 4 Presence of mutations in epigenetic regulators, organized by patient melanoma sample and key primary cutaneous melanoma
histopathologic parameters
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and TP53 (17p13) were among the most frequently mu-
tated genes within our cohort, in keeping with prior studies
and datasets [20, 31]. The latter two genes were also among
the genes within our cohort containing the highest number
and percentage of nonsense mutations, consistent with loss
of their tumor suppressive function. While mutations to
the TP53 gene have previously been considered a rare event
in melanomagenesis [32], our findings corroborate data
from others [20] demonstrating that they may be more
common than previously believed. While these large, publi-
cally available datasets have the advantage of pooling larger
number of patient melanoma samples, at present, they do
not allow for the specific characterization of UV-signature
mutations, nor do they allow for the direct comparison of
such patterns or others between epigenetic and non-
epigenetic genes, as our study has done. In addition, these
databases do not allow for potential relationships between
specific mutations and key melanoma histologic parameters
to be explored.
Our dataset and novel analytic approach, with an em-
phasis on epigenetic mutations, reveal several interesting
observations. Firstly, we identified a high frequency of
mutations in genes encoding epigenetic regulators in both
primary and metastatic cutaneous melanoma patient
samples with a statistically significant predilection for
mutations bearing the signature of UVB damage. Genes en-
coding histone-modifying proteins (e.g., MECOM, MLL2,
SETD2, etc.), subunits of chromatin-remodeling complexes
(e.g., ARID1B, ARID2), as well as units of the active DNA
demethylation pathway (TET2, IDH1) were the most
frequently mutated among this list. We took particular
interest in several novel standouts among our list of
most commonly mutated epigenetic genes. MECOM
(3q26), for instance, was among the most frequently mu-
tated genes (3.1 %, 23 of 740 mutations; 36.8 %, 14 of 38
patient samples) within our cohort of patient melanoma
samples and was higher than estimated by existing datasets
(Figs. 9 and 10) [30].
MECOM (MDS1 and EV1 complex locus) encodes
ecotropic viral integration site 1 (EVI1), an oncogenic
zinc finger transcription factor known to be overexpressed
in acute and chronic myeloid leukemia and to correlate
with poor patient survival [33, 34]. Interactome analysis
has revealed that the EVI1 oncoprotein exerts dynamic
nuclear functions and is involved in a number of vital
processes, including, but not limited to, transcription
regulation, DNA repair, recombination, and mitosis
[35]. In addition, EVI1 has been shown to interact with
Fig. 5 Ingenuity Pathway Analysis® of the 41 epigenetic regulators sequenced by our targeted next-generation sequencing platform (Oncopanel,
BWH/DFCI). Unique shape indicates key epigenetic function while the color reflects the prevalence of mutations in that gene
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multiple components of the epigenetic machinery, includ-
ing DNA methyltransferases, histone modifying enzymes,
and chromatin-remodeling complexes, including the
SWItch/Sucrose NonFermentable (SWI/SNF) nucleosome
remodeler [36]. Moreover, gene expression analyses
demonstrated a stem cell phenotype in EVI1-overexpress-
ing acute myelocytic leukemia cells, suggesting that this
oncoprotein could augment cancer stem cell self-renewal
capacity and facilitate disease progression and the develop-
ment of therapeutic resistance [36]. Similar lines of evi-
dence also suggest that EVI1 may be involved in facilitating
chemoresistance in human myeloid leukemias by inducing
the CDKN1A/p21/WAF complex [37]. Taken together, we
hypothesize that MECOM/EVI1 regulates the epigenetic
machinery enabling stem cell-like properties in specific
melanoma subpopulations. Additional studies are indicated
to explore and evaluate these possibilities.
MLL2 (or KMT2D, 12q13) was the second most fre-
quently mutated epigenetic gene within our cohort. MLL2
is a member of the myeloid/lymphoid or mixed-lineage
leukemia (MLL) family genes and encodes a specific his-
tone 3 lysine 4 (H3K4) methyltransferase, which provides
an evolutionarily conserved epigenetic mark for active
gene transcription [38]. Remarkably, all 16 of 16 muta-
tions in MLL2 bore the signature of UVB-induced DNA
damage. MLL2 was recently identified to extensively
regulate the expression of a number of critical cell signaling
pathways, including the p53 pathway and cAMP-mediated
signaling, as well as the expression of the retinoic acid-
responsive gene ASB2 [39]. Moreover, and of particular
interest to the biology of melanocytes and melanoma,
MLL2 was recently found to associate with the pro-
moters and thereby regulate the expression of S100
alpha (S100A) genes (1q21), which are known to control
cell cycle progression and differentiation within the mel-
anocyte [39]. MLL2 has been frequently implicated in the
pathogenesis of a number of human cancers [40–42], and
our findings corroborate with recent data [31] suggesting
the same may be true for malignant melanoma.
The IDH1 gene was also among the most commonly mu-
tated epigenetic genes within our collection and was more
frequently mutated than reported in prior studies [20].
IDH1 (2q33) encodes a soluble, cytoplasmic isocitrate
dehydrogenase 1 (IDH1) enzyme, an enzyme that converts
isocitrate to α-ketoglutarate (also known as 2-oxoglutarate)
[43]. Recent evidence suggests significant epigenetic conse-
quences resulting from mutations in this particular enzyme.
Loss of IDH1 function results in reduced production of
α-ketoglutarate, which is a necessary co-substrate for
two critical families of epigenetic regulators, including
histone demethylase enzymes and the ten-eleven trans-
location (TET) family of 5-methylcytosine hydroxylases,
Fig. 6 Spectrum of UV-signature mutations among non-epigenetic genes. Note the low frequency of UVB-signature mutations in BRAF
Lee et al. Clinical Epigenetics  (2015) 7:59 Page 8 of 17
otherwise known as Fe (II)-dependent dioxygenase
enzymes [44]. Furthermore, mutant IDH1 has been
demonstrated to lead to the accumulation of oncometabo-
lite 2-hydroxyglutarate (2-HG), which has been shown to
directly inhibit TET function [44, 45]. The TET family en-
zymes, composed of TET1, TET2, and TET3, are central
to the active DNA demethylation pathway [46, 47]. TET2
catalyzes the critical, iterative oxidation steps on the
methyl group of 5-methylcytosine to produce 5-hydroxy-
methylcytosine, 5-carboxylcytosine, and 5-formylcytosine,
and ultimately cytosine, after removal of the functional
group by thymine DNA glycosylase and the base excision
repair pathway [48]. This very recently uncovered pathway
has putative significance for maintaining DNA methyla-
tion and epigenetic fidelity, which has earned TET the
epithet “guardian of the epigenome” [12, 49].
5-hydroxymethylcytosine, an intermediate in DNA de-
methylation and a product of TET2 function is kinetically
the most abundant intermediate in this pathway [50]. Loss
of its nuclear immunopositivity has been demonstrated to
be a nearly universal hallmark of malignancy [51]. A
number of studies have demonstrated that, in most hu-
man organ systems, “loss of 5-hydroxymethylcytosine”
can distinguish malignant cellular proliferations from
the benign, wherein 5-hydroxymethylcytosine expression is
retained, with high sensitivity and specificity [13, 51–53].
Such observations bear testament to the pathobiologic
significance of TET enzyme dysfunction. Indeed, TET
has recently been found to interact in concert with an
array of epigenetic regulators, including transcription
factors, histone modifying enzymes, chromatin-remodeling
complexes, and miRNAs, suggesting a central regulatory
role over the epigenome [54]. A recent study documented
exceedingly rare somatic TET2 gene mutations in melan-
oma [55]. In contrast, six of 38 (15.8 %) of our human
melanoma samples had a documented mutation in TET2.
Moreover, when including IDH1-mutant samples, 21 %
(8 of 38) of patient samples had at least one mutation
affecting the critical DNA demethylation pathway in
which these two enzymes participate. That mutation to
Fig. 7 Spectrum of UV-signature mutations among epigenetic genes. Note the high frequency (100 %) of UVB-signature mutations among the
gene encoding histone lysine methyltransferase, MLL2 (KMT2D)
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the gene encoding the TET2 enzyme is only one of many
mechanisms that can cause its dysfunction [54] raises the
possibility that additional alterations not detectable by gen-
etic sequencing may, too, inhibit the function of this critical
regulator of the epigenome and contribute to melanoma
virulence.
Secondly, our dataset and analysis also identified a
high frequency of UVB-signature mutations among epi-
genetic genes. The genes encoding the central epigenetic
regulator MECOM/EVI1 (73.9 %, 17 of 23) and H3K4
methyltranferase MLL2 (100 %, 16 of 16) were found to
harbor the greatest overall number of UVB-signature
mutations. Both within and outside of the familial/her-
editary melanoma setting, ultraviolet light radiation
(UVR) is thought to play a major role in the pathogen-
esis of melanoma. While it is known that most of the
mutational burden in melanoma is attributable to the
mutagenic effects of UVR [56, 57], our findings raise the
possibility that UVR preferentially induces mutations in
genes encoding epigenetic regulators and/or that these
elements may be involved in mediating a physiologic
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Fig. 8 Distribution of UVB-signature mutations among non-epigenetic
genes and epigenetic genes. Collectively, epigenetic genes harbored a
significantly greater number of mean UVB-signature mutations than
non-epigenetic genes. Turquoise bar reflects the median among both
distributions
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response. This hypothesis is in keeping with the putative
role of epigenetic mechanisms at large in facilitating
changes in gene expression in response to environmental
cues [12, 58, 59] and could co-exist with pathways
known to be involved in the physiologic response of
melanocytes to UVR, such as the p53-proopiomelanocortin
(POMC) pathway [60]. Interestingly, we found that the
well-known oncogenes BRAF and NRAS had comparatively
low frequencies (26.3 and 0 %, respectively) of UVB-
signature mutations, a finding that is in keeping with previ-
ous studies [20]. In contrast, 81.8 % of CDKN2A mutations,
84.6 % of TP53 mutations, and 83.3 % of IDH1 mutations
resembled the UVB-signature mutation genotype in
our cohort.
Genomic evidence that epigenetic regulators may con-
tribute to melanoma pathogenesis was recently highlighted
by Hodis et al. [20], who found a high frequency of somatic
mutations in chromatin-modifying proteins and other
epigenetic regulators as well as a high frequency of UVB-
signature mutations in IDH1 and chromatin-modifying
enzymes ARID2 (a component of the SWI/SNF chromatin-
remodeling complex) and EZH2 (the histone lysine
methylase component of Polycomb-group gene silencing
complex). Ding et al. [31] also found a high frequency
of truncation mutations to chromatin-remodeling genes
(ASXL3, MLL2, ARID2) in their cohort of metastatic
melanoma cases [31]. Our findings, in addition to data
obtained from the COSMIC and TCGA melanoma data-
base (Figs. 11 and 12), contribute additional evidence to this
growing body of literature that dysregulated epigenetic
complexes and pathways may be more involved in the
pathobiology of melanoma than previously recognized. Our
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Fig. 10 Distribution of mutations in our “Top 40” genes among the Broad Institute cutaneous melanoma samples (n = 121) (data publicly
accessible via http://www.cbioportal.org)
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preliminary dataset indicate that genomic mutations to epi-
genetic regulators may be more common than previously
appreciated. Altogether, we found that approximately one
in five mutations occurred in a gene encoding an epigenetic
regulator, with mutations to histone-modifying enzymes
being the most common. Moreover, the overwhelming
majority (92.1 %, 35 of 38) of our patient samples har-
bored at least one mutation in an epigenetic regulatory
gene with well over half of all patients samples (65.7 %,
25 of 38) having more than one such gene mutated.
While our study provides novel insight into potential
epigenetic mechanisms involved in the pathogenesis of
melanoma, there are several limitations. Firstly, our mod-
estly sized cohort may under- or overestimate the fre-
quency of certain genetic mutations and also limits our
ability to identify a mutational signature, epigenetic or not,
that is typical of primary or metastatic melanoma tumors
or those that correlate with key histologic parameters that
confer a defined level of metastatic potential (i.e., depth,
mitotic rate). Further expansion and integration of
inter-institutional patient melanoma mutational profiles
alongside detailed, case-by-case clinical and histopathologic
annotation will be necessary to obtain the resolution neces-
sary to identify these critical relationships. Furthermore, the
lack of paired samples within our cohort reduces our ability
to identify or directly infer specific genetic mutations that
potentially drive metastasis or disease progression. Given
that the Oncopanel program at our institution is offered to
every oncology patient but is programmatically limited to
one test per patient due to economic constraints, our pa-
tient samples are unable to be paired. In addition, the panel
of epigenetic genes tested in our cohort is not comprehen-
sive, in view of the ever-expanding family of epigenomic
regulators [61], and additional sequencing platforms to test
for these novel epigenetic genes should be prepared for
further investigations. It must also be acknowledged that
sequencing techniques do not directly detect chromosomal
aberrations, which are known to occur and be involved in
the pathogenesis of melanoma [62] and distinguish benign
melanocytic lesions from malignant melanoma [63]. None-
theless, our study highlights the high prevalence of muta-
tions in epigenetic regulators in patient melanoma samples
and their tendency to bear the signature of UVB damage.
Moreover, our focus on utilizing genetic information to
understand dysregulated epigenetic mechanisms in melan-
oma provides a novel analytical lens that deserves further
consideration. Finally, our study demonstrates the clinical
application of next-generation sequencing to identify novel
mutations in melanoma and may shed light on new,
personalized pathogenic mechanisms and unveil potential
targets of therapeutic interest [21]. Because epigenetic
defects, unlike genetic mutations, are potentially reversible,
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this area of investigation has tremendous potential for
translational and therapeutic application.
Most existing non-immune based targeted therap-
ies attempt to inhibit proteins/enzymes that function
predominantly within and beneath the cell membrane and
cytoplasm, most of which participate in cell signaling path-
ways [64, 65]. Most such pathways are poised to influence
the expression of select genes, a process that is primarily
regulated by transcription factors and, very likely, other
functional binding partners, such as chromatin-remodeling
enzymes. As we continue to advance our understanding of
how epigenetic mechanisms interface with cell signaling
pathways and how their dysregulation, independently
or combined, contributes to diseases such as cancer,
opportunities for therapeutic targeting of pathobiologic
epigenetic mechanisms will follow. In parallel, evidence
is accumulating that multimodal combination therapy
will be critical for the successful treatment of biologically
complex malignancies such as melanoma [66]. Targeting
epigenetic mechanisms may provide one such adjunctive
avenue of attack, emphasizing the importance of delineat-
ing the relationships discussed above. Indeed, DNA methyl-
transferase inhibitors and histone deacetylase inhibitors are
the only current examples of existing FDA-approved ther-
apies that function in this manner, although they are not
currently in use for melanoma. Our data highlight several
candidate epigenetic regulators that deserve further investi-
gation and pathobiological characterization in melanoma.
Within our cohort, MECOM/EVI1, MLL2, and TET2/IDH
are examples of nuclear epigenetic regulators that we sus-
pect may be involved in the pathogenesis of melanoma and
could be involved in enabling stem-like characteristics in
select subpopulations. This epigenetic machinery deserves
thorough exploration in the context of melanoma pathobi-
ology, and further studies to establish their mutational
status in benign nevi are now indicated.
Conclusions
Herein, we describe the prevalence of somatic mutations
present in the genes encoding a spectrum of epigenetic
regulators within a cohort of treatment-naïve patient
melanoma specimens. We provide direct genomic evidence
that epigenetic regulators, including histone/chroma-
tin-modifying enzymes and DNA demethylation enzymes/
pathways may be involved in the development and/or pro-
gression of melanoma. Moreover, our analysis of patient
melanoma samples revealed a high prevalence of mutations
in epigenetic regulators with a quantifiable predilection
for those associated with UVB damage. In addition, we
have identified that MECOM, a novel, central epigenetic
regulatory gene, and TET2/IDH1, critical regulators of
DNA demethylation, are frequently mutated in patient
melanoma samples.
Availability of supporting data
The datasets supporting the results of this article are in-
cluded within the article and its additional file.
Methods
Ethics statement
The study was approved by the Institutional Review Board
of the Brigham and Women’s Hospital and Dana–Farber
Cancer Institute. Patients referred to our institution for the
evaluation and management of melanoma were offered an
opportunity to participate in this study. Informed consent
was obtained from 38 patients to collect a single sample of
their primary or metastatic tumor and have it sequenced
through the Oncopanel program. Oncopanel was designed
and implemented to provide an opportunity for every on-
cology patient seen and evaluated at the institution to have
their tumor tested. However, because its use is not cur-
rently being reimbursed, it is programmatically limited to
only one test per patient at the present time. All 38 patients
had not previously received any form of chemotherapy or
radiation for the treatment of their melanoma.
DNA was isolated from formalin-fixed melanoma
tissue using standard methods. Samples were incubated in
proteinase K overnight, followed by subsequent purifi-
cation of the DNA (QIAamp DNA Mini Kit, QIAGEN,
Gaithersburg, MD). DNA concentration was assessed
using PicoGreen dsDNA detection (Life Technologies,
Carlsbad, CA). Targeted NGS was performed using a
cancer genomic assay to detect mutations in the exonic
regions of 275 cancer genes previously implicated in
tumorigenesis and 91 intronic regions across 30 of the
275 genes (Oncopanel, BWH/DFCI, Additional file 1).
The complete coding sequence of the target genes was
captured using a solution-phase Agilent SureSelect hy-
brid capture kit (AgilentTechnologies, Inc., Santa Clara,
CA), and massively parallel sequencing was performed on
an Illumina HiSeq 2500 sequencer (Illumina, Inc. San
Diego, CA). Mutation calls were performed using Mutect
and GATK software (Broad Institute, Cambridge, MA).
Data analysis was performed using an internally devel-
oped bioinformatics Pipeline (Riker, REF) that was com-
posed of reconfigured publically available tools (GATK,
MuTect, Indelocator, Oncotator) and internally developed
algorithms (VisCap Cancer [REF], Phaser, BreaKmer3).
Reads obtained from pooled samples were demultiplexed
using Picard (http://picard.sourceforge.net/command-line-
overview.html), aligned to the Human Genome Reference
Consortium reference sequence GRCh37p13 (BWA5),
and duplicate reads were subsequently removed (Picard).
GATK6 was used to refine the alignments near insertion/
deletion (indel) sites. Single nucleotide variants (SNVs)
were called using MuTect7, and indels were called
using Indelocator (http://www.broadinstitute.org/cancer/
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cga/indelocator). Annotation was performed using Onco-
tator. Because tumor tissues were sequenced without a
paired normal from the corresponding patients, additional
informatic steps were taken to identify and account for
common single nucleotide polymorphisms (SNPS): any
SNP present at >0.1 % in Exome Variant Server (NHLBI
GO Exome Sequencing Project [ESP], Seattle, WA; URL:
http://evs.gs.washington.edu/EVS/) or present in dbSNP
was filtered. However, variants also present in the COSMIC
mutation database were rescued for manual review. Sam-
ples with a mean target coverage of <50X were failed and
excluded from further analysis. Individual variants present
at <10 % allele fraction or in regions with <50X coverage
were flagged for manual review and evaluated/interpreted
by the reviewing laboratory scientists and molecular pa-
thologists based on a variety of factors, including, but not
limited to, overall tumor percentage, read depth, complex-
ity of alteration, and evidence for associated copy number
alterations.
Mutation data was queried with Microsoft Sequel and
quantitatively analyzed with Microsoft Excel. Individual
gene mutation frequencies were calculated based on the
total number of mutations as well as based on the total
number of patients. Genes encoding proteins involved in
DNA methylation/demethylation, histone modification,
chromatin remodeling, or processing of non-coding RNAs
(such as microRNAs) were categorized as “epigenetic
regulatory genes”. Gene functions were determined by
referencing the genetic database (accessible at: http://
ghr.nlm.nih.gov/) provided by the United States Na-
tional Library of Medicine and the National Institute of
Health and supplemented by identifying recently published
literature available on PubMed documenting specific epi-
genetic function by a particular gene or its expressed pro-
tein. Quantitative data was analyzed using MedCalc version
13.2 (MedCalc Software, Ostend, Belgium) and StatPlus
version 5.8.2 (AnalystSoft Inc.). Statistical methods were
primarily descriptive and based on proportions and per-
centages. The proportion of epigenetic genes is presented
with a 95 % exact binomial confidence interval. Proportions
of epigenetic genes or mutations present within particular
cohorts were compared using chi-square analysis. All
p values were two-sided, with a p < 0.05 considered
statistically significant.
Additional mutation data was obtained from the publi-
cally available databases (http://www.cbioportal.org, Me-
morial Sloan Kettering Cancer Center, New York, NY)
provided by the National Institute of Health (NIH) and
National Cancer Institute (NCI) for the purposes of
comparison [22, 23]. In addition, to better understand
the relationships between mutated epigenetic regulators,
we performed Ingenuity Pathway Analysis (Qiagen, Red-
wood City, CA) to visualize direct relationships between
specific epigenetic regulators.
Additional file
Additional file 1: List of the 275 cancer gene exons as well as the
91 introns from 30 of these genes sequenced by our “Oncopanel”
cancer genomic assay.
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